Montag, 26. Juli 2021
Navigation öffnen
Anzeige:
Lenvima
Lenvima
 
JOURNAL ONKOLOGIE – STUDIE
GLOW

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Rekrutierend

NCT-Nummer:
NCT03653507

Studienbeginn:
September 2018

Letztes Update:
14.06.2021

Wirkstoff:
zolbetuximab, Oxaliplatin, Capecitabine, Placebo

Indikation (Clinical Trials):
Adenocarcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Astellas Pharma Global Development, Inc.

Collaborator:
-

Studienleiter

Medical Director
Study Director
Astellas Pharma Global Development

Kontakt

Astellas Pharma Global Development
Kontakt:
Phone: 800-888-7704
E-Mail: astellas.registration@astellas.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 178)

University of Southern California Norris Comprehensive Cancer Center
90033 Los Angeles
United StatesRekrutierend» Google-Maps
University of Kansas Cancer Center and Medical Pavilion
66205 Fairway
United StatesZurückgezogen» Google-Maps
Ochsner Clinic CCOP
70121 New Orleans
United StatesZurückgezogen» Google-Maps
New Mexico Oncology Hematology
87109 Albuquerque
United StatesRekrutierend» Google-Maps
Montefiore Medical Center (MMC)
10467 Bronx
United StatesRekrutierend» Google-Maps
Weill Cornell Medical College (WCMC)
10021 New York
United StatesRekrutierend» Google-Maps
Mercy Clinic Oncology and Hematology
73120 Oklahoma City
United StatesZurückgezogen» Google-Maps
Greenville Health System Cancer Center
29605 Greenville
United StatesRekrutierend» Google-Maps
University of Texas Southwestern Medical Center
75390 Dallas
United StatesRekrutierend» Google-Maps
Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology
77030 Houston
United StatesRekrutierend» Google-Maps
Utah Cancer Specialist
84106 Salt Lake City
United StatesRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

The study consists of the following periods: screening; treatment; post-treatment follow up,

safety follow up, long term and survival follow-up.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- A female subject is eligible to participate if she is not pregnant (negative serum

pregnancy test at screening; female subjects with elevated serum beta human chorionic

gonadotropin (βhCG) and a demonstrated non-pregnant status through additional testing

are eligible) and at least 1 of the following conditions applies:

- Not a woman of childbearing potential (WOCBP)

- WOCBP who agrees to follow the contraceptive guidance throughout the treatment

period and for 6 months after the final study treatment administration

- Female subject must agree not to breastfeed starting at screening and throughout the

study period, and for 6 months after the final study treatment administration.

- Female subject must not donate ova starting at screening and throughout the study

period, and for 6 months after the final study treatment administration.

- A male subject with female partner(s) of childbearing potential:

- must agree to use contraception during the treatment period and for 6 months

after the final study treatment administration.

- A male subject must not donate sperm during the treatment period and for 6 months

after the final study treatment administration.

- Male subject with a pregnant or breastfeeding partner(s) must agree to remain

abstinent or use a condom for the duration of the pregnancy or time partner is

breastfeeding throughout the study period and for 6 months after the final study

treatment administration.

- Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma.

- Subject has radiologically confirmed locally advanced unresectable or metastatic

disease within 28 days prior to randomization.

- Subject has radiologically evaluable disease (measurable and/or non-measurable disease

according to RECIST 1.1), per local assessment, ≤ 28 days prior to randomization. For

subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before

randomization, the lesion must either be outside the field of prior radiotherapy or

have documented progression following radiation therapy.

- Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to

strong membranous staining as determined by central IHC testing.

- Subject has a HER2-negative tumor as determined by local or central testing on a

gastric or GEJ tumor specimen.

- Subject has ECOG performance status 0 or 1.

- Subject has predicted life expectancy ≥ 12 weeks.

- Subject must meet all of the following criteria based on the centrally or locally

analyzed laboratory tests collected within 14 days prior to randomization. In case of

multiple central laboratory data within this period, the most recent data should be

used to determine eligibility.

- Hemoglobin (Hb) ≥ 9 g/dl. Subjects requiring transfusions are eligible if they

have a post-transfusion Hgb ≥ 9 g/dL.

- Absolute Neutrophil Count (ANC) ≥ 1.5x10^9/L

- Platelets ≥ 100x10^9/L

- Albumin ≥ 2.5 g/dL

- Total Bilirubin ≤ 1.5 x upper limit of normal (ULN) without liver metastases (or

< 3.0 x ULN if liver metastases are present)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

without liver metastases (or ≤ 5 x ULN if liver metastases are present)

- Estimated creatinine clearance ≥ 30 mL/min

- Prothrombin time/international normalized ratio (PT/INR) and partial

thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving

anticoagulation therapy)

Exclusion Criteria:

- Subject has received prior systemic chemotherapy for locally advanced unresectable or

metastatic gastric or GEJ adenocarcinoma. However, subject may have received either

neo-adjuvant or adjuvant chemotherapy as long as it was completed at least 6 months

prior to randomization.

- Subject has received radiotherapy for locally advanced unresectable or metastatic

gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered

from any related toxicity.

- Subject has received treatment with herbal medications or other treatments that have

known antitumor activity within 28 days prior to randomization.

- Subject has received systemic immunosuppressive therapy, including systemic

corticosteroids within 14 days prior to randomization. Subjects using a physiologic

replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day

of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of

systemic corticosteroids or receiving systemic corticosteroids as premedication for

radiologic imaging contrast use are allowed.

- Subject has received other investigational agents or devices within 28 days prior to

randomization.

- Subject has prior severe allergic reaction or intolerance to known ingredients of

zolbetuximab or other monoclonal antibodies, including humanized or chimeric

antibodies.

- Subject has known immediate or delayed hypersensitivity, intolerance or

contraindication to any component of study treatment.

- Subject has prior severe allergic reaction or intolerance to any component of CAPOX.

- Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency.

- Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome

with persistent/recurrent vomiting.

- Subject has significant gastric bleeding and/or untreated gastric ulcers that exclude

the subject from participation.

- Subject has a known history of a positive test for human immunodeficiency virus (HIV)

infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag))

or C infection. NOTE: Screening for these infections should be conducted per local

requirements.

- For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab)

positive, an HB deoxyribonucleic acid (DNA) test will be performed and if

positive, the subject will be excluded.

- Subjects with positive hepatitis C virus (HCV) serology, but negative HCV

ribonucleic acid (RNA) test are eligible.

- Subjects treated for HCV with undetectable viral load results are eligible.

- Subject has an active autoimmune disease that has required systemic treatment within

the past 3 months prior to randomization.

- Subject has active infection requiring systemic therapy that has not completely

resolved within 7 days prior to randomization.

- Subject has significant cardiovascular disease, including any of the following:

- Congestive heart failure (defined as New York Heart Association Class III or IV),

myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary

artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within

6 months prior to randomization.

- History of clinically significant ventricular arrhythmias (i.e., sustained

ventricular tachycardia, ventricular fibrillation or Torsades de Pointes

- QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female

subjects

- History or family history of congenital long QT syndrome

- Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate

controlled atrial fibrillation for > 1 month prior to randomization are

eligible).

- Subject has a history of central nervous system (CNS) metastases and/or carcinomatous

meningitis from gastric/GEJ cancer..

- Subject has known peripheral sensory neuropathy > grade 1 unless the absence of deep

tendon reflexes is the sole neurological abnormality.

- Subject has had a major surgical procedure ≤ 28 days prior to randomization.

- Subject is without complete recovery from a major surgical procedure ≤ 14 days

prior to randomization.

- Subject has psychiatric illness or social situations that would preclude study

compliance.

- Subject has another malignancy for which treatment is required.

- Subject has any concurrent disease, infection, or co-morbid condition that interferes

with the ability of the subject to participate in the study, which places the subject

at undue risk or complicates the interpretation of data.

Studien-Rationale

Primary outcome:

1. Progression Free Survival (PFS) (Time Frame - up to 13 months):
PFS is defined as the time from the date of randomization until the date of radiological progressive disease (per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by Independent Review Committee (IRC)) or death from any cause, whichever is earliest.



Secondary outcome:

1. Overall Survival (OS) (Time Frame - up to 23 months):
OS is defined as the time from the date of randomization until the date of death from any cause.

2. Objective Response Rate (ORR) (Time Frame - up to 13 months):
ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by Independent Review Committee (IRC) per RECIST 1.1.

3. Duration Of Response (DOR) (Time Frame - up to 13 months):
DOR, defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.

4. Safety and tolerability assessed by adverse events (AEs) (Time Frame - up to 16 months):
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

5. Number of participants with laboratory assessments abnormalities and or adverse events (Time Frame - up to 14 months):
Number of participants with potentially clinically significant laboratory values.

6. Number of participants with vital signs abnormalities and or adverse events (Time Frame - up to 14 months):
Number of participants with potentially clinically significant vital sign values.

7. Number of participants with electrocardiograms (ECG) abnormalities and or adverse events (Time Frame - up to 14 months):
Number of participants with potentially clinically significant ECG values.

8. Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events (Time Frame - up to 13 months):
Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

9. Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) (Time Frame - up to 16 months):
EORTC-QLQ-C30 is a cancer-specific 30-item questionnaire. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

10. Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Oesophago-Gastric Module 25 (QLQ-OG25) questionnaire plus EORTC-QLQ-STO22 Belching subscale (Time Frame - up to 16 months):
The EORTC-QLQ-OG25 instrument evaluates Gastric and Gastroesophageal Junction (GEJ) cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. It is a 25-item questionnaire. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much". To ensure relevant symptoms are adequately covered two questions from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC-QLQ-STO22) instrument related to belching and bile or acid coming in your mouth will be asked following the OG25 questionnaire. Participants rate items on a 4 point scale, with 1 as "not at all" and 4 as "very much". The total and subscale scores from the OG25 and item scores from the STO22 items will be reported.

11. Health Related Quality of Life (HRQoL) measured by the Global Pain (GP) questionnaire (Time Frame - up to 16 months):
The GP instrument is a single assessment of overall pain where 0 equals no pain and 10 equals extreme pain. Low pain scores are considered a better outcome than a high pain score.

12. Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) questionnaire (Time Frame - up to 16 months):
The EQ-5D-5L is a standardized instrument developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. The EQ-5D-5L is a 5-item self-reported measure of functioning and wellbeing, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

13. Pharmacokinetics (PK) of zolbetuximab: Concentration Immediately Prior to Dosing at multiple dosing (Ctrough) (Time Frame - up to 16 months):
Ctrough will be derived from the PK serum samples collected.

14. Number of anti-drug antibody (ADA) Positive Participants (Time Frame - up to 16 months):
Immunogenicity will be measured by the number of participants that are ADA positive.

Studien-Arme

  • Experimental: Arm A (zolbetuximab plus CAPOX)
    Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
  • Placebo Comparator: Arm B (placebo plus CAPOX)
    Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.

Geprüfte Regime

  • zolbetuximab (IMAB362):
    Zolbetuximab will be administered as a minimum 2-hour IV infusion.
  • oxaliplatin:
    Oxaliplatin will be administered as a 2-hour IV infusion.
  • capecitabine:
    Capecitabine will be administered orally twice daily (bid).
  • placebo:
    Placebo will be administered as a minimum 2-hour IV infusion.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose